PharmQuest Life Sciences, LLC

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes	Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus	Recruiting	Phase 3	2026-10-08	NCT07282600
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome	Dyslipidemias, Insulin Resistance, Lipid Metabolism Disorders, Lipidemia, Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hyperinsulinism, hyperlipidemia, metabolic disease, type 2 diabetes mellitus	Active, not recruiting	Phase 3	2026-09-09	NCT07219602
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity	Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition	Active, not recruiting	Phase 3	2026-07-20	NCT06662383

Clinical trials